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Abstract
Cervical cancer is considered a common yet preventable cause of death in women. It has been
estimated that about 420 women out of the 1400 women diagnosed with cervical cancer will die
during 5 years from diagnosis. This review addresses the pathogenesis of cervical cancer in humans
with a special emphasis on the human papilloma virus as a predominant cause of cervical cancer in
humans. The current understanding of apoptosis and regulators of apoptosis as well as their
implication in carcinogenesis will follow. A special focus will be given to the role of Rel/NF-κ B family
of genes in the growth and chemotherapeutic treatment of the malignant HeLa cervical cells
emphasizing on Xrel3, a cRel homologue.
Introduction
A. Oncogenesis
The process of oncogenesis or carcinogenesis fundamen-
tally emerges from defects in the balance between the
activity of proto-oncogenes, which promote cell prolifera-
tion, and tumor suppressor genes, which regulate the cell
cycle. It is known that DNA damage and repair occurs nor-
mally in every living cell. When the rate of DNA damage
exceeds that of repair, accumulation of DNA damage and
defects might trigger the initiation of cancer [[1-3] and
[4]].
Uterine cervical cancer is a serious gynecologic malig-
nancy in women. There are two main types of cervical can-
cer, squamous cell cancer and adenocarcinoma, based on
the type of cells that become cancerous. Cervical cancer is
initiated when the combined action of a group of carcin-
ogens cause the normal, physiological events associated
with cervical metaplastic transformation to go awry and
cause the formation of pre-malignant dysplasia [5]. Poor
prognosis is usually associated with positive pelvic lymph
nodes, indicating that the tumor cells have become meta-
static [6].
Recent studies have demonstrated that estrogen, which is
the female sex hormone, might have a contributory role in
increasing vaginal epithelium proliferation and thus pro-
moting the malignant transformation of the squamous
and columnar cells at the junction of the cervical and vag-
inal epithelium [7]. Infection by the Human Papilloma
Virus, HPV, is a necessary requirement for cervical cancer,
but not all women infected by this virus develop cervical
cancer [8]. Some HPV infections, for instance are associ-
ated with benign proliferation or wart formation.
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B. Human Papilloma Virus (HPV)
HPVs are small DNA viruses that are known to be the
most common etiological agents in cervical cancer [9].
More than 100 types of HPVs have been discovered, iso-
lated and studied (See Table 1) [10]. HPVs are implicated
in the mucosal and epithelial infections that may range
from a benign lesion to a malignant carcinoma [4]. HPV
has also been reported to be associated with anal and gen-
ital cancers [11]. Preliminary findings suggested their
involvement in some head and neck cancers as well [10].
The high risk HPV 16 and HPV 18 are associated with
malignant transformation and carcinogenesis in 85% of
the diagnosed cervical cancer cases [4]. Recent studies
have shown that 13 different types of HPV are associated
with carcinogenesis [3]. The most widely known factors
associated with HPV are the E6 and E7 oncoproteins,
which interact with p53 and Rb tumor suppressors respec-
tively [2]. The interaction of E6 and E7 with these cellular
proteins results in their suppression [9], thus disrupting
the normal physiological process of programmed cell
death in response to DNA damage (See Figure 1) [12]. In
Table 1: Naturally occurring cancers associated with papillomaviruses [10, 13].
Species Cancer Predominant viral types
Humans Skin carcinomas HPV-5, -8
Lower genital tract cancers HPV-16, -18, -31, -33
Malignant progression of respiratory papillomas HPV-6, -11
Cattle Alimentary-tract carcinoma HPV-4
Eye and skin carcinoma Not characterized
Sheep Skin carcinoma Not characterized
Cottontail rabbit Skin carcinoma Cotton rabbit papillomavirus (CRPV)
A schematic representation of RB/p53 interactions to regulate cell cycle and apoptosis Figure 1
A schematic representation of RB/p53 interactions to regulate cell cycle and apoptosis. Cell cycle transition from 
G1-S phase is mediated by RB interactions with the E2F transcription factor family, which is considered an important regulator 
of the cell cycle. Growth factors lead to the phosphorylation of RB in late G1 phase by cdk/cyclin. This is followed by the 
release of E2F, allowing transcriptional activation of E2F target genes, which promotes S-phase entry and cell proliferation. HPV 
E7 and Simian Virus 40 (SV40) promote the release of E2F from RB, whereas HPV E6 and the dominant negative, DN-p53 
inhibit p53 activity leading to cell proliferation.
E2F E2F
p53
HPV-E7
SV-40
Rb Cdk/cyclin
Cdk
inhibitor
-
Cell Proliferation
HPV-E
DN-
6
p53
-
+
ApoptosisCancer Cell International 2005, 5:10 http://www.cancerci.com/content/5/1/10
Page 3 of 13
(page number not for citation purposes)
the presence of carcinogens, therefore, the accumulation
of DNA damage without apoptosis is presumed to lead to
cancer.
It should be made clear that viral infection by itself does
not cause cancer. It is the interaction of the viral genome
with host genes that disrupts the normal cell cycle and
transforms the cell into a pre-malignant state. For
instance, some viruses might interact with specific genes
(like tumor suppressor genes mentioned above) in the
host cells, switching some systems on or off, thus leaving
the cell free to divide in an uncontrolled way and raising
the risk of cancer [13].
Other cellular proteins may be affected by HPV infection
as well. For instance, cervical cancer cell lines showed
overexpression of the anti-apoptotic protein BAG-1,
which might contribute to its malignant proliferation
[14]. Therefore, understanding the molecular mecha-
nisms leading to this disease will be of importance for
generating means for its early detection and possible pre-
vention and treatment.
C. Apoptosis
Apoptosis, or programmed cell death, is orchestrated by a
highly organized group of signaling pathway proteins
[[15] and [16]]. Apoptosis can be triggered by a variety of
events the cell may face. For example, exposures to X-rays,
ultraviolet light and chemotherapeutic drugs are factors
that can initiate the process of apoptosis [15].
One mechanism to protect an organism from the conse-
quences of accumulated DNA damage involves a class of
protein-splitting enzymes called caspases, which are acti-
vated upon detection of DNA damage and eventually
cause cell death [17]. The control of programmed or phys-
iological cell death acts as a protective mechanism for the
organism because accumulation of DNA damage without
concomitant repair could lead to the development of can-
cer, while unregulated apoptosis can cause autoimmune
diseases.
The process of apoptosis is essential in stopping the
uncontrolled proliferation of cells [18]. Any defects in this
dynamic process may eventually lead to the development
of benign proliferative lesions or even malignant tumors
[18]. Apoptosis can be initiated via specific receptors that
are members of the tumor necrosis factor (TNF) receptor
superfamily [19]. Such "Death receptors" are activated via
binding of specific ligands [19] and once they are acti-
vated, they can initiate apoptosis. However, the role of
these receptors is not restricted to the initiation of apopto-
sis, but also includes other functions that differ from
apoptosis and sometimes counteract apoptosis such as the
recruitment and subsequent ligand binding of growth fac-
tors such as the Nerve Growth Factor (NGF) [19].
Another apoptotic pathway involves the mitochondria.
Under stress, these essential organelles can release cyto-
chrome c into the cytoplasm of the cell [20]. This
cytochrome c release is a possible activator for caspases by
the recruitment of procaspase-9, which undergoes confor-
mational changes that leads to the activation of down-
stream, effector caspases [20].
Apoptosis acts as a double-edged sword. Despite its
importance in restricting cell proliferation and maintain-
ing constant cell number, excessive apoptosis is associated
with stroke, Alzheimer's disease and other neurodegener-
ative disorders [21]. Damaged neurons in these disorders
commit suicide inappropriately. Alzheimer's disease, for
instance, was found to be associated with a genetic com-
ponent that involves mutations in the chromosomes (1,
14, and 21) as well as the tau gene on chromosome 17
and results in unscheduled or unregulated death of brain
cells [22].
Understanding the details and the signaling pathways of
this phenomenon might be helpful in manipulating and
intervening in the process of apoptosis. Apoptosis is
required to restrict cell proliferation and to maintain a
constant cell number. Attempts to suppress apoptosis,
however, may be useful to treat neurodegenerative disor-
ders, while attempts to activate apoptosis may be useful in
disorders involving overproliferation.
D. Regulators of apoptosis
Many genes have been implicated in enhancing or inhib-
iting the process of apoptosis. They act by different mech-
anisms that ultimately contribute to either tumor
suppression or progression, respectively. Four of the most
important factors that regulate apoptosis are p53, the cas-
pases, the Bcl-2 family of proteins and PARP [[23,24], and
[25]].
1. Caspases
Caspases are the executioners of cell death. They receive
the signals that enable them to initiate apoptosis. Cells
undergoing apoptosis exhibit fragmentation of DNA, con-
densation of the chromatin, budding of the cell mem-
brane and the formation of apoptotic bodies by
dissociation of the cell and its constituents into mem-
brane-enclosed vesicles [[17] and [26]]. All caspases share
a similar structure that consists of three domains: an NH2-
terminal peptide (prodomain), a large subunit (approxi-
mately 20 kD) and a small subunit (approximately 10 kD)
[27]. Caspases are expressed as procaspases, which
undergo cleavage to the 2 subunits mentioned above [28].
Cleavage of caspases is a sign of active apoptosis. The largeCancer Cell International 2005, 5:10 http://www.cancerci.com/content/5/1/10
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and small subunits then associate to form a heterodimer
[[29] and [23]].
The exact mechanism of action of caspases is still
unknown. However, several studies have shown that cas-
pases exert both direct and indirect actions on the cell
[30]. The direct action of caspases can be exemplified by
their ability to act on cell structural integrity by destroying
the nuclear lamina [30] and cleaving the proteins respon-
sible for regulating the cytoskeleton [[30] and [31]]. The
indirect action of caspases is via their ability to inhibit the
proteins that promote cell survival and growth [27].
Among these proteins is the Bcl-2 family of proteins,
which are cleaved by caspases resulting in inactivation of
the Bcl-2 proteins and the release of a fragment that has a
direct apoptotic effect [30].
Caspases-8, -9, and -10 are known to initiate the caspase
activation cascade. However, caspases-3, -6 and -7 propa-
gate the cascade and are activated by the proteolytic cleav-
age process mediated by other upstream caspases in the
caspase cascade pathway [27].
2. Bcl-2 family of proteins
The Bcl-2 family of proteins has several members with var-
ious functions [18]. The Bcl-2 gene family comprises pro-
apoptotic and anti-apoptotic proteins sharing one or
more Bcl-2 homology (BH) domains [23]. The gene fam-
ily is made up of 3 main groups [27]. Group I includes the
anti-apoptotic members similar to Bcl-2. Group II
includes the pro-apoptotic members like Bax and Bak,
while group III comprises a diverse collection of proteins
that resemble one another structurally, but not necessarily
functionally. Bcl-2, BAG-1 and Bcl-xL provide a cell sur-
vival function [[14] and [32]]. However, Bax, which pro-
motes apoptosis translocates to the mitochondrial
membrane and releases cytochrome c, which can initiate
the apoptotic cascade [33]. It also competes for binding
with Bcl-2 and with other members of the Bcl-2 super-
family of proteins [33]. Such heterodimerization between
anti-apoptotic and pro-apoptotic members of this family
is very common and is considered a regulatory mecha-
nism for the decision to undergo apoptosis [23]. Thus, the
balance between Bcl-2 and Bax is essential for the determi-
nation of the apoptotic potential of the cells, in which
high apoptotic activity is often associated with a low Bcl-
2/Bax level ratio [23].
BAG-1 has been shown to provide an anti-apoptotic
effect. Its overexpression in cervical cancer suppressed
apoptosis both independently and by increasing Bcl-2
protective activity, which further increased the resistance
of cervical carcinoma to the effect of DNA-damaging
agents [14].
3. p53
The tumor suppressor protein p53 has numerous func-
tions (See Figure 1.2) [34]. Its principle role, however, is
as a transcriptional regulator required for the expression
of a number of genes involved in cell cycle regulation and
apoptosis. The gene encoding p53 can be mutated in
many forms of cancer including cervical, uterine, adeno-
carcinoma, adrenal and colorectal cancers. In cervical can-
cer, mutation patterns of p53 may vary from point
mutation to deletion to base-pair alteration, however
30% of the cases showed a higher percentage of Guanine-
Cytosine complementary base pairs compared to the Ade-
nine-Thymine complementary base pairs suggesting that
alteration in the base-pairing sequence is the major muta-
tion pattern recognized in p53 [34]. A recent clinical study
showed that the overexpression of p53 in cisplatin-treated
tumors might be associated with resistance of the tumor
to further cell death and apoptosis [35,36].
MDM2 is a p53-regulated protein that has a role in the
translocation of p53 from the nucleus and enhances its
proteosomal degradation [22]. Therefore, increased levels
of MDM-2 and subsequent low levels of p53 are associ-
ated with increased cell growth and proliferation. The p53
tumor suppressor protein can also be targeted for degrada-
tion by the E6 oncogene of the Human Papilloma virus
(HPV), thus promoting neoplastic proliferations (refer to
Figure 1) [34].
4. PARP
Poly (ADP-ribose) polymerase, PARP, has recently been
found to promote cell death, but the exact mechanism of
action of PARP remains largely obscure. Many cellular
enzymes were found to contain the PARP catalytic subu-
nit, but they have different cellular localizations. Because
PARP activation consumes much cellular energy, detec-
tion of abnormally high levels of PARP in cells might indi-
cate excessive energy consumption and cellular
exhaustion [22]. PARP is also known as an apoptosis-
inducing factor and high levels of PARP are detected fol-
lowing DNA damage. Thus, this group of enzymes might
also be involved in DNA repair, as well as apoptotic
responses of the cells (summarized in Figure 2) [22].
E. Rel/NF-κ B family
The first identified member of the nuclear factor-kappa
(κ )B (Rel/NF-κ B) family was a protein found to be associ-
ated with a decameric oligonucleotide sequence in the
enhancer element of the immunoglobulin kappa light
chain in B-lymphocytes [[37,38], and [39]]. The Rel/NF-
κ B family is now known to be made up of a plethora of
transcriptional regulators which share a 300 amino acid
terminal domain called the Rel homology domain (RHD)
[40,41]. This RHD comprises the DNA binding domain,
nuclear localization signal (NLS), dimerization domainsCancer Cell International 2005, 5:10 http://www.cancerci.com/content/5/1/10
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and the Iκ B binding domain (See Figure 3) [42,43]. Mem-
bers of this family include [37]:
1. NF-κ B, including p50, p65, p105 (mice devoid of p65
generated by targeted "knock-out" gene disruption
resulted in defects in fetal development localized to the
spleen and liver. However, knock-out mice devoid of
p105/p50  expression showed no defects during their
development).
2. Lyt-10 (p100), including p100 and p52, which are
required in spleen development.
3. c-rel (knock-out mice showed defects in the prolifera-
tion of B and T cells).
4. relB (knock-out mice showed defects in thymus
development).
5. Dorsal, which is involved in the formation of the dor-
sal-ventral axis of the fruit fly Drosophila [42].
Rel/nuclear factor of kappa B (NF-κ B) proteins include
those that do not require proteolytic processing and those
that do require proteolytic processing. The first group con-
sists of: RelA (known as p65), c-Rel and RelB. The second
group includes NF-κ B1 (known as p105) and NF-κ B2
(known as p100), which further produce p50 and p52
proteins, respectively (See Figure 3). Members of these
two groups pair with each other with the most commonly
detected NF-κ B being a heterodimer of p50 and RelA.
Summary of the mechanism of action of the tumor suppressor protein, p53 Figure 2
Summary of the mechanism of action of the tumor suppressor protein, p53. After DNA damage, the tumor sup-
pressor protein, p53, will be upregulated causing cell cycle arrest and enhancing DNA repair. However, in cases of irreversible 
DNA damage, p53 has been shown to transcriptionally repress the antiapoptotic gene Bcl-2, while it upregulates the pro-apop-
totic proteins Bax and Fas. This in turn, promotes apoptosis. During apoptosis loss of the integrity of the mitochondrial mem-
brane is followed by release of cytochrome c into the cytosol, this in turn leads to activation of caspase cleavage. Bax has been 
shown to contain p53-binding sites in its promoter site and is upregulated in response to DNA damage and increased p53 [36].Cancer Cell International 2005, 5:10 http://www.cancerci.com/content/5/1/10
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RelA is responsible for most of NF-κ B's transcriptional
activity due to the presence of a strong transcriptional acti-
vation domain at its C-terminus. p50-c-Rel dimers are less
abundant.
Both p50-RelA and p50-c-Rel dimers are regulated by
interactions with the inhibitor of κ B (Iκ B) proteins, which
cause their cytoplasmic localization. RelB, however,
mostly associates with p100 and the p100-RelB dimers are
exclusively cytoplasmic. Proteolytic processing of p100
results in the release of p52-RelB dimers, which then
translocate to the nucleus. RelB, unlike RelA and c-Rel, can
function as an activator or repressor [37,43]. Of the
above-mentioned proteins, only p50 and p52 are pro-
duced from the cytoplasmic precursors p105 and p100, in
the presence of ATP as an energy source [43]. However,
the other members contain trans-activation domains and
can act as activators or inhibitors of transcription based on
dimers containing or lacking trans-activation domains
(See Figure 3) [44].
The functions of the Rel/NF-κ B family of proteins are
strongly related to the target genes that contain the
response elements for the protein [[37,45,46], and [47]].
For example, κ B response elements are localized in IL-2,
IL-2R, Ig κ  and MHC Classes (I) and (II) genes, and here the
Rel/NF-κ B family of proteins function in modulating the
immune system responses by binding to these target
NF-κ B and Iκ B proteins Figure 3
NF-κ B and Iκ B proteins. A schematic representation of various domains in (Rel)/nuclear factor of kappa B (NF-κ B) proteins 
including the Rel Homology Domain, RHD, which comprises the DNA binding domain, nuclear localization signal (NLS), dimer-
ization domains and the Iκ B binding domain. (Rel)/nuclear factor of κ B (NF-κ B) proteins include those that do not require pro-
teolytic processing and those that do require proteolytic processing. The first group consists of: RelA (known as p65), c-Rel 
and RelB and the second group includes NF-κ B1 (known as p105) and NF-κ B2 (known as p100), which further produce p50 
and p52 proteins, respectively. These two groups dimerize, the most commonly detected NF-κ B dimer is p50 – RelA. RelA is 
responsible for most of NF-κ B transcriptional activity due to the presence of a strong transcriptional activation domain. p50 – 
c-Rel dimers are less abundant. Both p50 – RelA and p50 – c-Rel dimers are regulated by interactions with the inhibitor of κ B 
(Iκ B) proteins, which cause their cytoplasmic localization. RelB, however, mostly associates with p100 and the p100 – RelB 
dimers are exclusively cytoplasmic. Proteolytic processing of p100 results in the release of p52 – RelB dimers, which translo-
cate to the nucleus. RelB, unlike RelA and c-Rel, can function as an activator or repressor (Reproduced with permission from 
Nature Reviews Cancer (Vol 2, No. 4, pp 301#150;310 copyright (2002) Macmillan Magazines Ltd.).Cancer Cell International 2005, 5:10 http://www.cancerci.com/content/5/1/10
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sequences and recruiting other immune system and
inflammatory reaction mediators (See Figure 4 and Table
2). However, the Rel/NF-κ B family of proteins is also
directly involved in inflammatory reactions and acute
phase responses when the κ B binding sites are found in
the regulatory sequences for the IL-1, IL-6, TNF-α , TNF-β
and serum amyloid A protein genes. Also, the Rel/NF-κ B
family of proteins is involved in viral infections when the
κ B sites are found in the HIV-LTR, SV 40, CMV and aden-
ovirus. Other functions of Rel/NF-κ B proteins include
growth regulation, immune system responses and cell
adhesion molecules (see Table 2).
Activation of NF-κ B transcription involves the transloca-
tion of NF-κ B proteins to the nucleus as illustrated in
Figure 4 [[37,42,43,48] and [49]]. The factors involved in
the transcriptional activation of different members of the
Rel/NF-κ B family are mentioned in Table 3.
The steps involved in the activation of NF-κ B family of transcription factors (Reproduced from Ponnappan, 1998, Feb 01;  3:d152-68 with permission from Frontiers in Bioscience) Figure 4
The steps involved in the activation of NF-κ B family of transcription factors (Reproduced from Ponnappan, 
1998, Feb 01; 3:d152-68 with permission from Frontiers in Bioscience). Activators of NF-κ B like TNF-alpha, PMA, 
UV or LPS activate the NF-κ B inducible kinase, which in turn phosphorylates at least IKK1 (I kappa B kinase-alpha) and some-
times IKK2 (I kappa B kinase-beta) in the I kappa B-kinase complex. Activators of NF-κ B may directly activate the kinase com-
plex as well. This may be followed by phosphorylation of the p105/p65 complex by the kinase complex, which is in turn 
followed by ubiquitination, proteasomal degradation and the nuclear translocation of NF kappa B. Inside the nucleus; NF kappa 
B promotes the transcription of immune response genes. The "??????" indicates the possibility of lowered translocation and 
consequent activation of NF-κ B, which occurs in various diseases.Cancer Cell International 2005, 5:10 http://www.cancerci.com/content/5/1/10
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F. Iκ B inhibitor system
The multiple targets of Rel/NF-κ B proteins and their mul-
tiple modes of regulation indicate that this family pos-
sesses diversity in function. Interestingly, their major
mode of regulation appears to be well conserved through
the Iκ B inhibitor system. Iκ B is a protein of 60–70 kDa
[[38] and [43]]. The Iκ B inhibitor system comprises seven
molecules Iκ B-α , Iκ B-β , Iκ B-γ , Bcl-3, p105, p100 and I κ B
R [45]. The inhibitor of κ B (Iκ B) kinase (IKK) complex is
composed of two catalytic subunits, IKKα  and IKKβ , and
one regulatory subunit, IKKγ .
The Iκ B inhibitor system regulates NF-κ B (p50, p65) by
retaining it as a complex in the cytoplasm [54]. As a result,
the NF-κ B family members remain in the cytoplasm in an
inactive form. In response to stimuli such as tumour-
necrosis factor-α  (TNF-α ), CD40 ligand (CD40L), inter-
leukin-1 (IL-1) or lipopolysaccharide (LPS), the IKKβ  sub-
unit is activated, and phosphorylates the Iκ B proteins
(bound to the NF-κ B heterodimers) at two conserved ser-
ines. This phosphorylation event triggers the ubiquitin-
dependent degradation of Iκ B by the 26S proteasome,
resulting in the nuclear translocation of RelA-p50 (or c-
Rel-p50) heterodimers and transcriptional activation of
target genes (See Figure 5). In response to other stimuli,
such as the TNF family members lymphotoxin B (LTβ )
and BAFF, IKKα  is activated to induce the phosphoryla-
tion of p100 (bound to RelB) at two serine residues at its
carboxyl terminus. This phosphorylation event triggers
the ubiquitin-dependent degradation of the carboxy-ter-
minal half of p100, releasing its amino-terminal half, the
p52 polypeptide, which together with its heterodimer
partner, RelB, translocates to the nucleus to activate tran-
scription [[38,43], and [45]] (See Figure 5 and Table 4).
Rel/NF-κ B family members also cooperate with other
transcriptional regulators such as the non-Rel/NF-κ B pro-
tein Ets-1. Recent data has provided evidence that physical
interaction between Ets and NF-kappaB proteins is
required for the transcriptional activity of the HIV-1 and
HIV-2 enhancers [47]. These interactions represent a
potential target for the development of novel immuno-
suppressive and antiviral therapies.
G. Role of NF-κ B in apoptosis and cell survival
The dual role of NF-κ B in enhancing or inhibiting apop-
tosis and cell death has attracted much attention in regard
to its role in carcinogenesis.
NF-κ B involvement in apoptosis
The role of Rel/NF-κ B proteins in apoptosis has been well
studied [[50] and [51]]. NF-κ B, for instance, was found to
be activated following TNF-α -induced apoptosis in sev-
eral cell lines [52]. Treatment of cell lines derived from
acute B-cell leukemia and human thymocytes with etopo-
side was found to activate NF-κ B and this activation
occurred prior to the initiation of apoptosis [44]. Further
evidence supporting the involvement of NF-κ B in
apoptosis is the presence of NF-κ B binding sites in the
genes encoding IL-1β  converting enzyme protease, c-myc, and
TNFα , which are all involved in apoptosis and cell death
[[44] and [53]]. Also, several studies showed that p65 is
involved in apoptosis. This was based on an original
observation whereby inhibition of apoptosis was
achieved by overexpression of a dominant-negative p65
protein [54].
Table 2: Localization of κ B binding motifs in the body suggests the functions of Rel/NF-κ B [37].
κ B sites Related functions
IL-2, IL-2R, Igκ , MHC Classes I and II Immune system reaction and responses.
IL-1, IL-6, TNF-α , TNF-β , serum amyloid A protein Inflammatory reactions and acute phase responses.
HIV-LTR, SV 40, CMV, adenovirus Viral infections
Rel/NF-κ B family (NF-κ B1, NF-κ B2, c-rel, RelB) Immune system responses.
p53, c-Myc, Ras, pRB1 Growth regulation.
Iκ B-α , Iκ B-γ , p105, p100 and Bcl-3 Iκ B family members
I-CAM, V-CAM, E-selectin, ELAM1 Cell adhesion molecules
Table 3: The factors associated with activation of NF-κ B 
transcription factor [37] and [42].
• Cytokines (TNF-α , IL-1, IL-2, IL-6)
• Bacterial lipopolysaccharides
• Phytohemagglutinin (PHA)
• Cross-linking surface CD2, CD3, CD28 and T-cell receptors.
• Proteins secreted by viruses, for example, tax, X, E1A
• Viral infections, for example, HIV-1, Hepatitis B, HSV, HTLV-1
• Antigenic stimulants for the T and B-cells receptors
• Ultraviolet light exposure
• X-irradiation
• Nitric oxide
• Hydrogen peroxide and other oxidizing agents
• Calcium ionophoresCancer Cell International 2005, 5:10 http://www.cancerci.com/content/5/1/10
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Illustration of the Rel/NF-κ B pathway Figure 5
Illustration of the Rel/NF-κ B pathway. In response to stimuli such as tumour-necrosis factor-α  (TNF-α ), CD40 ligand 
(CD40L), interleukin-1 (IL-1) or lipopolysaccharide (LPS), the IKKβ  subunit is activated, and phosphorylates the Iκ B proteins 
(bound to the NF-κ B heterodimers) at two conserved serines. This phosphorylation event triggers the ubiquitin-dependent 
degradation of Iκ B by the 26S proteasome, resulting in the nuclear translocation of RelA – p50 (or c-Rel – p50) heterodimers 
and transcriptional activation of target genes [48].
Table 4: Steps involved in Rel/NF-κ B activation [42].
Steps involved in Rel/NF-κ B activation
1. Exposure to a stimulus that activates NF-κ B such as UV light.
2. Degradation of Iκ B or its inactivation by phosphorylation by means of protein kinases (McKenzie et al., 2000).
3. Dissociation of the complex between NF-κ B family members and Iκ B inhibitor system.
4. Translocation of NF-κ B proteins to the nucleus.
5. DNA binding of NF-κ B proteins.
6. Transcriptional induction by NF-κ B proteins.
Activators
Virus
TNF-a
IL-1
lpha
PMA
LPS
Signal transduction
cascade
Viral
Products
Eg. HIV-1 Tat 
HTLV-1 Tax 
EBV LMP-1
Rel/NF-țBp
P65(Rel A
roteins
)
roteins
n
RelB
C-Rel
P50
p52
Immune cell activation 
Anti-apoptosis
Stress reponse 
Antiviral and
antimicrobial resonses
Control of viral gene 
expression
IțBp
IțB-alpha
IțB-beta
IțB-epsilo
IțB-gamma
Bcl-3
P105
p100 Ikk activation
p50 p65
IkB-alpha
p50 p65
IkB-alpha
RNA transcriptionCancer Cell International 2005, 5:10 http://www.cancerci.com/content/5/1/10
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Rel/NF-κ B role in cell protection and survival
The role of Rel/NF-κ B proteins in cell survival is generally
associated with their ability to upregulate the expression
of myc [[55] and [56]]. Myc is a protein that mediates the
transcriptional activation of cyclin A and cyclin D3, which
are cell cycle regulators. A decrease in the myc protein con-
centration in the cell has been associated with apoptosis.
Another pathway that leads to high myc levels is through
the stimulation of CD40, a member of TNF receptor fam-
ily, which results in NF-κ B activation [57] and whose
stimulation has been implicated in cell survival and pro-
tection [57].
The role of Rel/NF-κ B as a factor in both cancerous and
normal cell survival is well documented. Recent results,
for instance, have shown NF-κ B to be activated in the early
malignant transformation of mammary cells of the breast
[58]. Furthermore, NF-κ B is constitutively active in pan-
creatic adenocarcinoma in humans [59], in T-cell
leukemia cells [60], in human breast cancer [61] and in
head and neck squamous cell carcinoma cell lines [62].
In non-cancer cells, NF-κ B was reported to be essential for
the growth and survival of sympathetic nerve cells inde-
pendently of the de novo protein synthesis [63]. Further
evidence of severe liver degeneration was associated with
lack of NF-κ B activation [64]. This was based on the death
of murine embryonic fibroblasts that lack detectable NF-
κ B DNA binding activity in response to TNF-α , LPS, IL-1
and do not show Iκ B kinase activity required for NF-κ B
activation [64].
The anti-apoptotic activity of Rel/NF-κ B can be regulated
by other proteins. For instance, the X chromosome-linked
inhibitor of apoptosis (XIAP) induces NF-κ B activation by
increasing the nuclear translocation of its p65 subunit
[56]. In addition, CD95, which is known as Fas and pos-
sesses an apoptotic effect, was found to stimulate NF-κ B
degradation by caspases [66], but when an antibody
against CD95 was used, caspases were inhibited and the
inducibility of NF-κ B was restored [66].
H. Xrel3
Xrel3 encodes an embryonic protein found to be related to
the rel family of proteins. The Xrel3 gene is present in the
genome of the amphibian, Xenopus laevis and is
expressed in and is essential for the normal development
of the head of Xenopus laevis embryos [67]. Xrel3 is also
normally expressed in the otocysts and notochord of the
embryonic larval stages [67]. Interestingly, Xrel3 overex-
pression has been implicated in the development of epi-
dermal tumors in embryos [[14] and [67]], but little is
known about how these tumors form, or whether they
have similar properties to human tumors. Investigating
whether the Xrel3 protein had properties that could con-
tribute to human cancer has been explored by many
researchers [[68,69] and [70]]. By applying what is known
about the role of Xrel3 in embryos to human cell lines, it
may be possible to uncover new knowledge about the
mechanism of Rel/NF-κ B activity in general.
In addition to its ability to cause embryonic tumor forma-
tion, the rationale for studying the effects of Xrel3 in
human cervical cancer cells has basis in practicality. When
a DNA vector encoding tagged-Xrel3 was transiently trans-
fected into HeLa cells, Xrel3 protein constitutively local-
ized in the nuclei, suggesting its ability to be active
constantly in mammalian cells [68]. In addition, HeLa
cells do not normally express Rel/NF-κ B, so the transfec-
tion of Xrel3 into these cells gives the opportunity to study
the activity of an interesting Rel/NF-κ B protein in a nega-
tive background [[69] and [70]]. Therefore, even though
Xrel3 is not a mammalian gene, its homology to the mam-
malian Rel/NF-κ B family indicates that it may serve as a
good model for gene regulation by this family enabling us
to understand the mechanism of action of the Rel/NF-κ B
family of transcriptional regulators in cancer cells.
I. Cancer Chemotherapy
Many chemical agents are used in the treatment of cancer.
Some can be used alone in single therapy and others have
to be combined or added to other regimens for an effec-
tive outcome. The five groups of single chemotherapeutic
agents are: alkylating agents, antimetabolites, plant
derivatives, antitumor antibiotics and the miscellaneous
group which contains the platinums, procarbazine, mito-
tane and gallium nitrate.
Platinums
The platinum-containing compounds are carboplatin, cis-
platin and oxaliplatin. This group of chemotherapeutic
drugs is very effective in monotherapy regimens [71].
They are the most active agents in the treatment of ovarian
and cervical cancers. However, they are associated with
three major drawbacks [72]:
1. Severe toxicity in the form of nephrotoxicity, ototoxic-
ity, myelosuppression and peripheral neuropathy.
2. Narrow range of tumors upon which they are effective.
3. The development of resistance after a short period of
treatment.
New approaches are now designed in an attempt to
expand the mechanism of action of platinums. This is
done by developing a new generation of platinum-con-
taining compounds that exhibited a broader spectrum of
activity on different tumors, lower toxicity potential as
well as delayed resistance to treatment [71].Cancer Cell International 2005, 5:10 http://www.cancerci.com/content/5/1/10
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Cisplatin
Cis DiamminedichloroplatinII (cisplatin) is one of the
platinum-containing anti-cancer agents. It can be recog-
nized from its chemical name that the cis form is the
active form of the drug. The trans form was found to pos-
sess no biologic activity [72]. The mechanism of action of
cisplatin is similar to the alkylating agents, but it is not
identical. Cisplatin works by promoting DNA cross-link-
ing and chelation. Recent clinical studies have shown that
improved cytotoxicity of cisplatin can be attained by
increasing the exposure time of the tumor to the drug
[73].
J. Rel/NF-κ B and Chemoresistance
Many researches have attempted to investigate the role
that NF-κ B family might have in chemotherapeutic resist-
ance. Activation of the Rel/NF-κ B was found to be associ-
ated with chemotherapeutic resistance by suppressing the
apoptotic potential of the chemotherapeutic drug. Recent
data demonstrate that the protection from apoptosis
induced in response to carbonyloxycamptothecin (CPT-
11) treatment is effectively inhibited by the transient inhi-
bition of NF-κ B in a variety of human colon cancer cell
lines [74]. This might be due to the cell survival effects
associated with the upregulation of Rel/NF-κ B family as
previously mentioned. In addition, genetic manipulation
aimed at inhibiting Rel/NF-κ B, was found to cause sensi-
tization of different tumor cells, like lung cancer cells, to
the effect of chemotherapeutic drugs [75]. This makes the
Rel/NF-κ B family an attractive set of proteins to study in
chemoresistant tumors.
The urge for overcomming the resistance encountered by
the prolonged usage of chemotherapeutic drugs necessi-
tates a deeper understanding of the underlying pathways
that favors cell survival and inhibits apoptosis. An
investigation of the upregulation of NF-κ B might be a
promising field of study in this regard since Rel/NF-κ B
activation has been associated with chemoresistance.
Regarding chemotherapy, cisplatin can be used as a mon-
otherapy without any adjuvant chemotherapeutic drugs.
Cisplatin is also used in the treatment of gynecologic can-
cers like ovarian cancers [72]. Previous studies have
shown that the apoptotic effect induced by chemotherapy
in cervical cancer involves the apoptosis factor p53 and
the HPV-E6 oncogenes and might be enhanced or attenu-
ated depending on the platinum carrier ligand [76].
Recent studies by Shehata et al. investigated the effect of
Xrel3 overexpression on the growth of HeLa cells with and
without chemotherapeutic treatment [[69] and [70]].
Results showed that Rel/NF-κ B might be a possible cause
of chemotherapeutic resistance encountered in cervical
cancer cells. This was observed at low doses of cisplatin
treatment, where larger population of the malignant HeLa
cells was present as compared to control cells transfected
with an empty vector. However, at high concentrations of
cisplatin, the upregulated Xrel3 enhanced apoptosis syn-
ergistic with cisplatin. This implies that Xrel3, a cRel
homologue, possesses a dual apoptotic and antiapoptotic
effect based on the degree of stress the cell might be facing.
References
1. Anonymous:  National Cancer Institute of Canada.  Canadian
Cancer Statistics 2003.
2. Furomoto HIM, Irahara : Human papilloma virus (HPV) and cer-
vical cancer. J Med Invest 2002, 49:124-133.
3. Munoz N, Bosch FX, Sanjose S, Herrero R, Castellsague X, Shah KV,
Snijders PJ, Meijer CJ, International Agency for Research on Cancer
Multicenter Cervical Cancer Study Group: Epidemiologic classifi-
cation of human papillomavirus types associated with cervi-
cal cancer. N Engl J Med 2003, 348:518-527.
4. Garland SM: Human papillomavirus update with a particular
focus on cervical disease. Pathology 2002, 34:213-224.
5. Josefson D: Mild cervical dysplasia often reverts to normal.
BMJ 1999, 318:420.
6. Kim CJ, Jeong JK, Park M, Park TS, Park TC, Namkoong SE, Park JS:
HPV oligonucleotide microarray-based detection of HPV
genotypes in cervical neoplastic lesions. Gynecologic Oncology
2003, 89:210-217.
7. Park JS, Rhyu JW, Kim CJ, Kim HS, Lee SY, Kwon YI, Namkoong SI,
Sin HS, Um SJ: Neoplastic change of squamo-columnar junc-
tion in uterine cervix and vaginal epitheluim by exogenous
estrogen in hpv-18 URR E6/E7 transgenic mice small star,
filled. Gynecologic Oncology 2003, 89:360-368.
8. Castellsague X, Bosch FX, Munoz N: Environmental co-factors in
HPV carcinogenesis. Virus Research 2002, 89:191-199.
9. Ghim SJ, Basu PS, Jenson A: Cervical Cancer: Etiology, Patho-
genesis, Treatment, and Future Vaccines. Asian Pac J Cancer
2002, 3:207-214.
10. Sisk EA, Robertson ES: Clinical implications of human papillo-
mavirus infection. Front Biosci 2002, 1:e77-e84. Finzer,P, Lemarroy
AA, Rosl F (2002). The role of human papillomavirus oncoproteins E6
and E7 in apoptosis. Cancer Letters, 188, 15-24
11. Heilmann V, Kreienberg R: Molecular biology of cervical cancer
and its precursors. Curr Womens Health Rep 2002, 2:27-33.
12. Finzer P, Lemarroy AA, Rosl F: The role of human papillomavi-
rus oncoproteins E6 and E7 in apoptosis. Cancer Letters 2002,
188:15-24.
13. zur Hausen A, van Beek J, Bloemena E, ten Kate FJ, Meijer CJ, van den
Brule AJ: No role for Epstein-Barr virus in Dutch hepatocellu-
lar carcinoma: a study at the DNA, RNA and protein levels.
J Gen Virol 2003, 84(7):1863-1869.
14. Yang X, Hao Y, Ferenczy A, Tang SC, Pater A: Overexpression of
Anti-apoptotic Gene BAG-1 in Human Cervical Cancer.
Experimental Cell Research 1999, 247:200-207.
15. Miller LJ, Marx J: Apoptosis. Science 1998, 281:1301-1304.
16. Fiers W, Beyaert R, Declercq W, Vandenabeele P: More than one
way to die: apoptosis, necrosis and reactive oxygen damage.
Oncogene 1999, 18:7719-7730.
17. Thornberry NA, Lazebnik Y: Caspases: Enemies Within. Science
1998, 281:1312-1316.
18. Nicholson DW: From bench to clinic with apoptosis-based
therapeutic agents. Nature Insight 2000, 407:810-816.
19. Ashkenazi A, Dixit VM: Death receptors: Signalling and
Modulation. Science 1998, 281:1305-1308.
20. Green DR, Reed JC: Mitochondria and Apoptosis. Science 1998,
281:1309-1312.
21. Yuan J, Yanker BA: Apoptosis in the nervous system. Nature
Insight 2000, 407:802-809.
22. Rich T, Allen RLWAH: Defying death after DNA damage. Nature
Insight 2000, 407:777-783.
23. Reed JC: Double identity for proteins of the Bcl-2 family.
Nature 1997, 387:773-776.
24. Packham G, Brimmell M, Cleveland JL: Mammalian cells express
two differently localized Bag-1 isoforms generated by alter-
native translation initiation.  Journal of Biochemistry 1997,
328:807-813.Cancer Cell International 2005, 5:10 http://www.cancerci.com/content/5/1/10
Page 12 of 13
(page number not for citation purposes)
25. Green DR: Apoptotic Pathways: Paper Wraps Stone Blunts
Scissors. Cell 2000, 102:1-4.
26. Savill J, Fadok V: Corpse clearance defines the meaning of cell
death. Nature Insight 2000, 407:784-788.
27. Hengartner MO: The biochemistry of apoptosis. Nature Insight
2000, 407:770-776.
28. Meier P, Finch A, Evan G: Apoptosis in development.  Nature
Insight 2000, 407:796-801.
29. Boise LH, Gottschalk AR, Quintans J, Thonpson CB: Bcl-2 and Bcl-
2-related proteins in apoptosis regulation. Curr Top Microbiol
Immunol 1995, 200:107-121.
30. Evan G, Littlewood T: A Matter of Life and Cell Death. Science
1998, 281:1317-1322.
31. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ,
Ebb RG, Subramanian T, Chittenden T, Lutz RJ: Bik, a novel death-
inducing protein shares a distinct sequence motif with Bcl-2
family proteins and interacts with viral and cellular survival-
promoting proteins. Oncogene 1995, 11(9):1921-1928.
32. Stuart JK, Myszka DG, Joss L, Mitchell RS, McDonald SM, Xie Z,
Takayama S, Reed JC, Ely KR: Characterization of Interactions
between the Anti-apoptotic Protein BAG-1 and Hsc70
Molecular Chaperones. The Journal of Biological Chemistry 1998,
273:22506-22514.
33. Ferrer I, Planas AM: Signaling of cell death and cell survival fol-
lowing focal cerebral ischemia: life and death struggle in the
penumbra. J Neuropathol Exp Neurol 2003, 62(4):329-339.
34. Rosenthal AN, Ryan A, Al-Jejani RM, Storey A, Harwood CA, Jacobs
IJ: p53 codon 72 polymorphism and risk of cervical cancer in
UK. Lancet 1998, 352:871-874.
35. Nakayama K, Takebayashi Y, Nakayama S, Hata K, Fujiwaki R, Fuku-
moto M, Miyazaki K: Prognostic value of overexpression of p53
in human ovarian carcinoma patients receiving cisplatin. Can-
cer Letters 2003, 192:227-235.
36. Famuboni AK, Graveling AJ, Markey AL, Minns FC, Patel A: Apopto-
sis. 2002 [http://www.portfolio.mvm.ed.ac.uk/studentwebs/session2/
group28/index.html].
37. Verma IM, Stevenson JK, Schwarz EM, Antwerp DV: Rel/NF-κ B/Iκ B
family: intimate tales of association and dissociation. Genes
and Development 1995, 9:2723-2735.
38. Baeuerle PA, Baltimore D: Iκ B: A Specific Inhibitor of the NF-κ B
Transcription Factor. Science 1988, 242:540-546.
39. Govind S: Control of development and immunity by Rel tran-
scription factors in Drosophila. Oncogene 1999, 18:6875-6887.
40. Castranova V, Chen F, Shi X, Demers LM: New Insights into the
Role of Nuclear Factor-κ B, a Ubiquitous Transcription Fac-
tor in the Initiation of Diseases. Clinical Chemistry 1998, 45:7-17.
41. Gerondakis S, Grossmann M, Nakamura Y, Pohl T, Grumont R:
Genetic approaches in mice to understand Rel/NF-κ B and
Iκ B function: transgenics and knockouts.  Oncogene 1999,
18:6888-6895.
42. Liou HC, Baltimore D: Regulation of the NF-κ B /rel transcrip-
tion factor and Iκ B inhibitor system. Current Opinion in Cell biology
1993, 5:477-487.
43. May MJ, Ghosh S: Signal transduction through NF-κ B. Immunol-
ogy Today 1998, 19:80-88.
44. Beg AA, Baldwin AS Jr: The Iκ B proteins: multifunctional regu-
lators of Rel/NF-κ B trancription factors. Genes and Development
1993, 7:2064-2070.
45. Garcia GE, Xia Y, Chen S, Wang Y, Ye RD, Harrison JK, Bacon KB,
Zerwes HG, Feng L: NF-κ B-dependent fractalkine induction in
rat aortic endothelial cells stimulated by IL-1beta, TNF-
alpha, and LPS. Journal of Leukocyte Biology 2000, 67:577-584.
46. Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baeuerle
PA: Rapid proteolysis of I kappa B-alpha is necessary for acti-
vation of transcription factor NF-kappa B.  Nature 1993,
365:182-185.
47. Bassuk AG, Anandappa RT, Leiden JM: Physical interactions
between Ets and NF-kappaB/NFAT proteins play an impor-
tant role in their cooperative activation of the human immu-
nodeficiency virus enhancer in T cells. Journal of Virology 1997,
71(5):3563-3573.
48. Hiscott J, Kwon H, Genin P: Hostile takeovers viral appropria-
tion of the NF-kB pathway. J Clin Invest 2001, 107(2):143-151.
49. Shain KH, Jove R, Olashaw NE: Constitutive RelB Activation in
v-Src-Transformed Fibroblasts: Requirement for I κ B
Degradation. Journal of Cellular Biochemistry 1999, 73:237-247.
50. Hogerlinden MV, Rozell BL, Richter LA, Toftgard R: Squamous Cell
Carcinomas and Increased Apoptosis in Skin with Inhibited
Rel/Nuclear Factor-κ B Signaling.  Cancer research 1999,
59:3299-3303.
51. Manna SK, Mukhopadhyay A, Aggarwal BB: Resveratrol Sup-
presses TNF-Induced Activation of Nuclear Transcription
Factors NF-κ B, Activator Protein-1, and Apoptosis:
Potential Role of Reactive Oxygen Intermediates and Lipid
Peroxidation. The Journal of Immunology 2000, 164:6509-6519.
52. Miyamoto S, Maki M, Schmitt MJ, Hatanaka M, Verma IM: Tumor
necrosis factor alpha-induced phosphorylation of I kappa B
alpha is a signal for its degradation but not dissociation from
NF-kappa B. Proc Natl Acad Sci U S A 1994, 91(26):12740-12744.
53. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T:
Transcriptional regulation of endothelial cell adhesion mole-
cules: NF-kappa B and cytokine-inducible enhancers. FASEB J
1995, 9(10):899-909.
54. Higgins KA, Coleman TA, McComas WA, Perez JR, Dorshkind K,
Sarmiento UM, Rosen CA, Narayanan R: Antisense inhibition of
the p65 subunit of NF-kappa B blocks tumorigenicity and
causes tumor regression.  Proc Natl Acad Sci U S A 1993,
90(21):9901-9905.
55. Foo SY, Nolan GP: NF-κ B to the rescue.  Trends Genet 1999,
15:229-235.
56. Chen F, Castranova V, Shi X: New Insights into the Role of
Nuclear Factor-κ B in Cell Growth Regulation. American Journal
of Pathology 2001, 159:387-397.
57. Madrid LV, Wang CY, Guttridge DC, Schottelius AJG, Baldwin AS Jr,
Mayo MW: Akt Suppresses Apoptosis by Stimulating the
Transactivation Potential of the RelA/p65 Subunit of NF-κ B.
Molecular and Cellular Biology 2000, 20:1626-1638.
58. Kim DW, Sovak MA, Zanieski G, Nonet G, Romieu-Mourez R, Lau
AW, Hafer LJ, Yaswen P, Stampfer M, Rogers AE, Russo J, Sonenshein
GE: Activation of NF-κ B/Rel occurs early during neoplastic
transformation of mammary cells.  Carcinogenesis 2000,
21:871-879.
59. Wang W, Abbruzzese JL, Evans DB, Chiao PJ: Overexpression of
urokinase-type plasminogen activator in pancreatic adeno-
carcinoma is regulated by constitutively activated RelA.
Oncogene 1999, 18:4554-4563.
60. Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW,
Yamamoto N: Constitutive Activation of NF-κ B in Primary
Adult T-Cell Leukemia Cells. Blood 1999:2360-2368.
61. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr: Selec-
tive activation of NF-κ B subunits in human breast cancer:
potential roles for NF-κ B2/p52 and for Bcl-3. Oncogene 2000,
19:1123-1131.
62. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV,
Mukaida N, Waes CV: Constitutive Activation of Transcription
Factors NF κ B, AP-1, and NF-IL6 in Human Head and Neck
Squamous Cell Carcinoma Cell Lines that Express Pro-
inflammatory and Pro-angiogenic Cytokines.  Molecular
Carcinogenesis 1999, 26:119-129.
63. Maggirwar SB, Sarmiere PD, Dewhurst S, Freeman RS: Nerve
Growth Factor-Dependent Activation of NF-κ B Contributes
to Survival of Sympathetic Neurons. The Journal of Neuroscience
1999, 18:10356-10365.
64. Rudolph D, Yeh WC, Wakeham A, Rudolph B, Nallainathan D, Potter
J, Elia AJ, Mak TW: Severe liver degeneration and lack of NF-
κ B activation in NEMO/IKKγ -deficient mice.  Genes and
Development 2000:854-862.
65. Stehlik C, Rainer de Martin , Kumabashiri I, Schmid JA, Binder BR, Lipp
J:  Nuclear Factor (NF) – κ B -regulated X-chromosome-
linked iap Gene Expression Protects Endothelial Cells from
Tumor Necrosis Factor α -induced Apoptosis. J Exp Med 1998,
188:211-216.
66. Ravi R, Bedi A, Fuchs EJ, Bedi A: CD95 (Fas)-induced Caspase-
mediated Proteolysis of NF-κ B.  Cancer research 1998,
58:882-886.
67. Lake BB, Ford R, Kao KR: Xrel3 is required for head develop-
ment in Xenopus laevis. Development 2001, 128(2):263-273.
68. Green A: Effect of Xrel3 on TGF-β  Signalling Pathway in
Human Cervical Cancer cells. M e m o r i a l  U n i v e r s i t y  o f
Newfoundland; 2003. Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cancer Cell International 2005, 5:10 http://www.cancerci.com/content/5/1/10
Page 13 of 13
(page number not for citation purposes)
69. Shehata M, Shehata M, Shehata F, Pater A: Dual apoptotic effect of
Xrel3 c-Rel/NF-kappaB homolog in human cervical cancer
cells. Cell Biol Int 2004, 28(12):895-904.
70. Shehata M, Shehata M, Shehata F, Pater A: Apoptosis Effects of
Xrel3 c-Rel/Nuclear Factor-Kappa B homolog in Human
Cervical Cancer Cells. Cell Biol Int  in press.
71. Fuertes MA, Castilla J, Alonso C, Perez JM: Novel concepts in the
development of platinum antitumor drugs. Curr Med Chem Anti-
Canc Agents 2002, 2:539-551.
72. Reedijk J: New Clues for platinum antitumor chemistry:
Kinetically controlled metal binding to DNA. National Academy
of Sciences 2003, 100:3611-3616.
73. Markman M: Intraperitoneal antineoplastic drug delivery:
rationale and results. The Lancet Oncology 2003, 4:277-283.
74. Cusack JC Jr, Liu R, Baldwin AS Jr: Inducible Chemoresistance to
7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamp-
tothecin (CPT-11) in Colorectal Cancer Cells and a
Xenograft Model Is Overcome by Inhibition of Nuclear
Factor-κ B Activation. Cancer Research 2000, 60:2323-2330.
75. Jones DR, Broad M, Madrid LV, Baldwin AS Jr, Mayo MW: Inhibition
of NF-κ B sensitizes non-small cell lung cancer cells to chem-
otherapy-induced apoptosis. Ann Thorac Surg 2000, 70:930-936.
76. Koivusalo R, Krausz E, Ruotsalai n e n  P ,  H e l e n i u s  H ,  H i e t a n e n  S :
Chemoradiation of Cervical Cancer Cells: Targeting Human
Papillomavirus E6 and p53 Leads to Either Augmented or
Attenuated Apoptosis Depending on the Platinum Carrier
Ligand. Cancer research 2002, 62:7364-7371.
77. Ponnappan U: Regulation of transcription factor NFkappa B in
immune senescence. Frontiers in Bioscience 1998, 3:D152-168.